Our potential upside, page-9

Just so everyone is fully armed with correct information - NTI has access to all off the Dolce strains - NTI is neuro, Dolce non neuro which is mostly skin applications. NTI is a drug discovery and development company - current trials plus proposed orphan drug strategy means NTI could have a FDA registered drug within 18 months - orphan drug and off label use (see NEU for market comparable and our upside potential).

The lodged patents are for a combination of rarer cannabinoids used together (we are not CBD and have shown completely different modes of action in the human body compared to CBD and THC) - the patent is not the plant , not THC , not CBD - international patent searches and patent attorneys confirm no prior art and no reason to suggest patents wouldn't be successful - you are entitled to your half glass empty approach but when NTI hits $500m plus market cap (on its way to $1bn) - don't say we didn't tell you the real upside value proposition of NTI.